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Introduction 
The quest for alternative drugs to the well-known cisplatin and its derivatives, which are still used in 
more than 50% of the treatment regimes for patients suffering from cancer, is highly needed.teyssot1, 2 
Indeed, despite their tremendous success, these platinum compounds suffer from two main 
disadvantages: they are inefficient against platinum-resistant tumors, and they have severe side-effects 
such as nephrotoxicity. The latter drawback is the consequence of the fact that the ultimate target of 
these drugs is ubiquitous: It is generally accepted that Pt anticancer drugs target DNA, which is 
obviously present in all cells.3, 4 Furthermore, as a consequence of its particular chemical structure, 
cisplatin in particular offers little possibility for rational improvements to increase its tumor-specificity 
and thereby reduce undesired side effects.  
In this context, organometallic compounds, which are defined as metal complexes containing at least 
one direct, covalent metal-carbon bond, have recently been found to be promising anticancer drug 
candidates. Organometallics have a great structural variety (ranging from linear to octahedral and even 
beyond), far more diverse stereochemistry than organic compounds (for an octahedral complex with six 
different ligands, 30 stereoisomers exist!), and, by rational ligand design, provide control over key 
kinetic properties (such as hydrolysis rate of ligands). Furthermore, they are kinetically stable, usually 
uncharged, relatively lipophilic and their metal atom is in a low oxidation state. Due to these 
fundamental differences compared to “classical coordination metal complexes”, organometallics offer 
new opportunities in the design of novel classes of medicinal compounds, potentially with new metal-
specific modes of action. Interestingly, all the typical classes of organometallics such as metallocenes, 
half-sandwich, carbene-, CO- or -ligands, which have been widely used for catalysis or biosensing 
purposes, have now also found application in medicinal chemistry (see Figure 1 for an overview of 
these typical classes of organometallics). 
In this perspective article, we report on the recent advances in the discovery of organometallics with 
proven anti-proliferative activity. We are emphasizing those compounds, where efforts have been made 
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to identify their molecular target and mode of action by biochemical or cell biology studies. This 
perspective covers more classes of compounds and in more detail than a recent tutorial review by 
Hartinger and Dyson.5 Furthermore, whereas recent reviews and book contributions attest to the rapid 
development of bioorganometallic chemistry in general,6, 7 this perspective focuses on their potential 
application as anticancer chemotherapeutics. Another very recent review article makes and attempt to 
categorize inorganic anticancer drug candidates by their mode of action.8 We should mention that a full 
description of all currently investigated types of compounds is hardly possible any more in a concise 
review. For example, a particularly promising class of organometallic anticancer compounds, namely 
radiolabeled organometallics, has been omitted for space limitations. Recent developments of such 
compounds have been reviewed in detail by Alberto.9 
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Figure 1. Summary of the typical classes of organometallic compounds used in medicinal chemistry.  
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Metallocenes. Metallocenes is the name for compounds with two -bonded cyclopentadienyl (Cp) 
ligands on a metal atom. Research into this class of compounds started in 1952 with the discovery of 
ferrocene (bis-cyclopentadienyl iron, Cp2Fe) and the elucidation of its C5-symmetric structure with two 
equivalent, -bonded Cp rings. Due to their symmetrical structure, such compounds are also frequently 
referred to as "sandwich complexes". Today, other metal complexes with cyclic -perimeters are also 
sometimes named metallocenes. Compounds with only one -perimeter are classified as "half-sandwich 
metallocenes", such as the Ru(arene) complexes discussed below in some of the following sections of 
this perspective. Structurally, the bis-cyclopentadienyl complexes can be classified into two classes, 
namely the "classical" ones with parallel Cp rings and the “bent” metallocenes, which have other 
ligands bonded to the metal in addition to the Cp rings (Scheme 1). Chemically sufficiently robust 
classical metallocenes for medicinal applications contain metals from the iron and cobalt triad, with Fe, 
Ru and Co being relevant to this article. The bent metallocenes typically comprise metals from the 
earlier transition metals, most importantly Ti, Zr, V, Nb, Mo in a medicinal context. Interestingly, all 
medicinally important bent metallocenes have a cis-dihalide motif as depicted in Scheme 1, which is 
similar to the cis-dichloro motif of the well-established anticancer drug cisplatin. This resemblance has 
spurred interest in metallocenes in the early days of medicinal inorganic chemistry, particularly through 
the work of Köpf and Köpf-Maier.10-12	
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Scheme 1. Top row: Classical metallocenes with parallel Cp rings (left) and bent metallocenes (right) 
with the medicinally relevant metals indicated. Below: Reversible oxidation chemistry of ferrocene. 
 
Historically, however, the medicinal properties of ferrocene were previously investigated as it was the 
first organometallic compound for which anti-proliferative properties were reported.13 This report 
sparked the development of organometallic anticancer compounds.14, 15 Ferrocene by itself is not a 
particularly toxic compound. It can be injected, inhaled, or taken orally without causing major health 
problems. Like most xenobiotics, it is degraded in the liver by cytochromes. Because of its aromatic 
character, a metabolism related to benzene had been expected and was indeed found experimentally. As 
shown in experiments with rats that were orally given a single dose of ferrocene in sesame oil, ferrocene 
is enzymatically hydroxylated in the liver and urinally excreted in the form of conjugates to sulphate 
(minor product) and glucuronic acid as the main product.16 In vitro, intact liver microsomes, NADPH 
and molecular oxygen were found necessary for the hydroxylation of ferrocene. This process was 
inhibited in vitro by CO, but significantly stimulated in vivo by pre-treatment of the rats with 
phenobarbital. These findings give a conclusive evidence that the hydroxylation of ferrocene is carried 
out by cytochrome P450 enzymes, much like benzene and many other hydrocarbons are. Although such 
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studies have hardly been carried out on other organometallic complexes, it is not unreasonable to 
assume that a similar fate is experienced by several of the metal-based drugs discussed in this article, at 
least by those who possess -bonded (quasi-aromatic) ligands. On the other hand, hydroxyferrocene is 
rather unstable and decomposes in aqueous solution, finally releasing solvated iron atoms. Indeed, 
ferrocene derivatives have been proposed as anti-anaemics and one such compound, ferrocerone, was 
clinically approved in the USSR. To the best of our knowledge, this compound was the first marketed 
transition organo-metal drug. In this context, it is worth mentioning that another ferrocene-containing 
compound, which is a close derivative of chloroquine, has sucessfully passed clinical phase II trials as 
an anti-malarial drug candidate (ferroquine, 1, Figure 2).17, 18 This compound is now undergoing field 
testing and may reach approval as a new anti-malarial drug in the near future. Ferroquine has an activity 
similar to chloroquine on the malaria parasite P. falciparum, but most notably is similarly active against 
chloroquine-resistent P. falciparum strains. It has been discussed that changes in lipophilicity, but 
possibly also some redox-activation, could be responsible for the unexpected activity of this ferrocene 
anti-malarial.18 Following the success of ferroquine, many other organometallic anti-malarials were 
synthesized and tested, but as yet with lesser success.  
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Figure 2. Ferroquine (1) is presently the most advanced organometallic drug candidate and about to 
enter phase III clinical trials as an anti-malarial drug.  
 
The toxicity of ferrocene was also tested in beagle dogs which were fed up to 300 mg kg-1 per day for 
six months, or even 1 g kg-1 up to three months.19 While no acute toxicity or even deaths were observed, 
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massive Fe overload was diagnosed. However, the dogs recovered afterwards. The ferrocene-induced 
hepatic Fe overload could be reduced after the removal of large quantities of Fe by repeated 
venesection.19  
Ferrocene can undergo a one-electron oxidation, yielding the ferrocenium cation (see Scheme 1, 
bottom). This cation is rather stable and the redox reaction is reversible for most ferrocene derivatives. 
Simple ferrocenium salts were the first iron compounds for which an anti-proliferative effect on certain 
types of cancer cells was demonstrated.13 The mechanism of action is still uncertain. Nuclear DNA, cell 
membrane, and the enzyme topoisomerase II20, 21 were proposed as possible targets. More precisely, 
Osella et al. showed that ferrocenium salts may generate hydroxyl radicals in physiological solutions.22 
An earlier report suggests that these radicals damage the DNA in a Fenton-type reaction.23 The 
cytotoxic effect of decamethylferrocenium tetrafluoroborate (Cp*2FeBF4, Cp* = pentamethyl-
cyclopentadienyl) was correlated to the production of 8-oxoguanine, the initial product of DNA 
oxidation. Direct evidence for hydroxyl and superoxide radicals stems from ESR and spin-trapping 
experiments. In one of the few studies of this kind, a synergistic effect between Cp*2FeBF4 and the iron-
dependent anti-tumor drug bleomycin was observed.24 Finally, the cell membrane may be the cellular 
target similar to the peroxidation of membrane lipids which is the consequence of excess hepatic iron. A 
more detailed review on the physiological chemistry of ferrocene and the anti-proliferative properties of 
ferrocene or ferrocenium alone has recently been given elsewhere.25  
Neuse et al. used an interesting approach to enhance the cytotoxicity of ferrocene. They bound 
ferrocene to polymeric supports such as poly-aspartamide.26-30 The underlying idea is that enhanced 
water solubility may be a crucial factor for the activity of ferrocene. This assumption is confirmed by 
the fact that the cytotoxicity of ferricenium salts depends greatly on the nature of the counterion. Indeed, 
the poorly soluble heptamolybdate is inactive while ferricenium salts with good aqueous solubility such 
as the picrate and trichloroacetate display high anti-tumour activity.13 It must be noted that smaller 
ferrocenyl polyamines were also tested by Brynes and co-workers at almost the same time, but with 
9 
limited success.31 The work on polymer-bound ferrocene as anticancer drugs has recently been reviewed 
by Neuse.32 
Numerous ferrocene derivatives have been tested for anti-proliferative purposes.33-38 Among those, a 
ferrocene-acridine conjugate was found to be highly cytotoxic. The acridine moiety served to bring the 
ferrocene close to DNA by intercalation.36 Wagner and co-workers investigated the activity of borylated 
ferrocenes in Boron Neutron Capture Therapy (BNCT)34 and found that their compounds exhibit an 
interesting organ distribution. One derivative in particular was found to penetrate the blood-brain barrier 
(BBB), which is of high importance for the treatment of brain tumors. Schmalz and co-workers 
synthesised several nucleoside analogues of ferrocene39 (e.g. 2 in Figure 3) with LD50 values in the low 
M range, although not as high as the iron-tricarbonyl nucleoside analogues from the same group (see 
also section on Metal carbonyl complexes below).40, 41 No molecular target has been proposed so far for 
2, but the structure makes protein targets, maybe in RNA / DNA synthesis or repair pathways, likely 
candidates. 
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Figure 3. A nucleoside analogue of ferrocene.  
 
In more general terms, redox activity is a property that is not unique to metal compounds, but 
frequently encountered in those. It is thus interesting to correlate the redox properties of metal 
compounds with electron transfer, oxidative stress, the formation of reactive oxygen species, and 
generally the redox status of cells.33, 42 While it is difficult to determine the exact "redox potential" or 
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even "redox status" of a whole cell, the correlation between the redox activity of metal complexes and 
their anti-proliferative properties has been only tentatively investigated. However, a mechanism 
whereby redox activation induces anticancer activity in ferrocene derivatives has recently been 
suggested by Jaouen and co-workers.42 They substituted phenyl rings in established drugs and natural 
products by ferrocene groups.43 Most significantly, this work has uncovered a group of derivatives of 
the anticancer drug tamoxifen, called ferrocifens by Jaouen's group.42, 44 Tamoxifen (3 in Figure 4) is the 
front-line chemotherapeutic agent for patients with hormone-dependent breast cancer. Its active 
metabolite is hydroxy-tamoxifen (4 in Figure 4). In general, breast tumours can be divided into two 
groups depending on the presence (ER(+)) or absence (ER(-)) of the estrogen receptor. About two thirds 
of all cases belong to the ER(+) type, rendering them susceptible to hormone therapy by selective 
estrogen receptor modulators (SERMs) such as tamoxifen, and giving the patients significantly 
improved chances for successful treatment compared to the ER(-) group of patients.42 The 
antiproliferative action of tamoxifen arises from the competitive binding to ER subtype, thus 
repressing estradiol-mediated DNA transcription in the tumor tissue. Unfortunately, expression of the 
ER may become down-regulated under tamoxifen treatment, turning the drug ineffective.  
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Figure 4. Tamoxifens and ferrocifens. The most active derivative of 5 with n = 4 is referred to as the 
ferrocifen.  
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It is believed that the same principle explains the activity of ferrocifens (5) against ER(+) cancer cell 
lines. Some SARs were derived from a group of ferrocene derivatives of tamoxifen as shown in Figure 
4. Replacement of the phenyl group by ferrocene reduces receptor affinity to about 40 %. Increasing the 
length of the dimethylamino-alkyl chain has an adverse effect on receptor binding. In addition, it also 
changes the bioavailability and determines whether estrogenic or anti-estrogenic activity is observed in 
animal experiments. It appears that an optimum value is around n = 4. While the Z isomers bind more 
strongly to the ER than the E isomers in in vitro tests, there is rapid isomerization under physiological 
conditions. Finally, ferrocifens were shown to be effective anti-estrogens in MCF-7 breast cancer cell 
lines (ER(+)) and against estrogen-dependent tumour xenografts in nude mice.  
Surprisingly, however, compound 5 with n = 4 was shown to be active against the ER(-) MDA-
MB231 tumour cell line, which lacks the ER and is hence not susceptible to treatment with 
tamoxifens. This indicates a new and different mode of action for 5. Interestingly, the ruthenocene 
analogue of 5 also acts as an antiestrogen in ER(+) breast cancer cells but lacks the antiproliferative 
effect of ferrocifen against ER(-) cell lines.45 Other organometallic fragments in place of the ferrocenyl 
group were also tested, but were found to be inactive.44, 46 This suggests a dual mode of action for 
ferrocifen. In addition to tamoxifen-like binding to the ER receptor, the second pathway must critically 
depend on the properties of ferrocene. In an elegant study, redox activation has been proposed as the 
second mode of action.47 The active metabolite hydroxyferrocifen is readily oxidized, yielding a 
quinone methide intermediate. This intermediate is activated for nucleophilic attack by nucleophiles. 
Quinone methides of the metal-free 4-hydroxytamoxifen are known to be stable for hours under 
physiological conditions. Adducts of such tamoxifen metabolites with glutathione and nucleobases are 
thought to be responsible for its general toxicity and mutagenic potential. It is now proposed that related 
chemistry applies to the activated ferrocifens. Extensive SAR studies48-53 in correlation with 
electrochemical properties52, 54-56 support this hypothesis. Moreover, production of reactive oxygen 
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species has been demonstrated in cell lines treated with ferrocifen and derivatives.57 In this mode of 
action, which is summarized in Scheme 2, the metallocenes serves as a "redox antenna". It is 
particularly noteworthy that redox activity of the metallocene is the key for additional biological activity 
that exceeds that of a purely organic analogue. Once this redox-activation mode of action was 
established, it is clearly not dependent on the tamoxifen-related substructure. Recently, the same group 
has presented work on ferrocenyl diphenols and unconjugated phenol derivatives which also have good 
anti-proliferative activity, presumably via a related mechanism of activation and formation of similar 
intermediates.58, 59 
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Scheme 2. Redox activation of ferrocifens as proposed by Jaouen and co-workers. The ferrocene 
serves as a "redox antenna", following oxidation and proton abstraction a quinone methide is formed, 
which is readily attacked by nucleophiles at the positions indicated by arrows. 
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In order to advance the use of ferrocifens towards clinical studies, several formulation studies were 
performed using nanoparticles,60 lipid nanocapsules,61, 62 and cyclodextrins.63 Further work from the 
same group includes, beyond synthesis, at least a preliminary testing of the anti-proliferative activity of 
ferrocene derivatives of several classes of compounds, i. e. curcuminoids,64 androgen derivatives65 and 
anti-androgens derived from the nilutamide lead structure,66 indolones,67 and ferrocenophane 
polyphenols.68 
 
For the bent metallocene dihalides, SARs were established for the halides and substitution of the Cp 
rings11, 14, 15, 69 and model studies of such compounds with amino acids, nucleic acids, proteins and blood 
plasma were performed.70 Titanium compounds were most active, and titanocene dichloride has even 
entered clinical trials.71 Although very promising in animal models, the clinical response was not 
encouraging enough to justify continuing trials – i.e. titanocene dichloride clinical trials were recently 
abandoned. Furthermore, due to its decomposition and low solubility in water, there were also problems 
with the formulation of the drug. Earlier work investigated DNA interaction, induction of apoptosis and 
topoisomerase inhibition as possible modes of action.72-74 
Despite the resemblance of titanocene dichloride with cisplatin, there has never been a clear evidence 
of an identical mode of action – i.e. binding to DNA and eventually apoptosis of the cancer cell.4 
Instead, binding of the Ti4+ cation to transferrin following complete hydrolysis of Cp2TiCl2 was 
proposed,75 and even a stimulatory effect of aqueous Ti species on hormone-dependent breast cancer 
cells was observed.46 From an inorganic point of view however, the existence of simple hydrated Ti4+ 
cations is highly unlikely in aqueous solution at pH 7, as oligomeric species and eventually insoluble 
titanium dioxide will form. A recent computational study on a benzyl-substituted titanocene (titanocene 
Y (6), Figure 5) suggests that the Cp(R)2Ti2+ dication binds to a DNA phosphate group, with additional 
interactions stabilizing the binding to DNA.76 Although this result is in accord with chemical intuition, 
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i.e. the hard Ti cation binding to anionic oxygen atoms, it is a single point computation assuming DNA 
as the molecular target. No protein targets were so far considered for the bent metallocenes. 
 
The two main problems of the titanocene dihalides, i.e. poor aqueous solubility and hydrolytic 
instability were both addressed in recent years by chemical synthesis. To increase aqueous solubility, 
amino-substituted bent metallocenes were successfully prepared.77 The two Cp rings are covalently 
linked together in ansa-titanocenes and indeed, such compounds exhibit improved hydrolytic stability.78, 
79 Both groups of compounds show promising biological activity. The group of Tacke has developed a 
versatile synthetic access to Cp-substituted bent metallocenes via the fulvene route. This approach 
yields unbridged (via hydrido-lithiation) as well as ansa-bridged metallocenes (via carbo-lithiation).80  
In vitro cytotoxicity tests were performed for several derivatives. A screen against 36 human tumor cell 
lines of 14 different tumor types on the derivatives 6 - 8 (termed titanocenes Y, X and Z, Figure 5) 
revealed the p-methoxy-benzyl substituted titanocene Y (6) as the most active derivative. Even more 
interesting, this compound showed very good activity against renal cell cancer and pleura mesothelioma 
cell lines, for which no effective chemotherapeutic agents are currently available.81 Further testing of 
this compound was performed, including tests against freshly explanted tumors82, 83 and in vivo tests 
against xenografted renal cancer (Caki-1),84 prostate cancer (PC-3),85 and breast tumor (MCF-7) in 
mice.82 Mechanistic studies particularly, but not exclusively, on titanocene Y revealed anti-angiogenic 
effects but no myelosuppression,86 activation of the immune system, and induction of apoptosis via 
caspases 3 and 7, but not caspase-8.87, 88 This is a desirable combination of properties for anticancer 
drugs. In an obvious extension of their work and inspired by second-generation platinum drugs, the 
Tacke group has recently replaced the two chloride ligands on titanocene Y by carboxylate groups to 
yield equally active compounds with possibly even more favourable pharmacokinetics.89, 90 
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Figure 5. Titanocene Y (6), and the ansa-bridged derivatives titanocenes X (7) and Z (8).  
 
While Cp-substituted vanadocenes, zirconocenes, and even stannocenes were recently evaluated,91-94 
more in-depth research has concentrated on molybdocene derivatives as the most promising alternative 
to Cp2TiCl2. Again with relation to cisplatin, DNA was envisaged as the target and in early work, 
several X-ray structures with the Cp2Mo fragment coordinated to nucleobases were obtained.95-97 Also 
early on, comparative hydrolysis studies of several bent metallocene dihalides were performed which 
identified Cp2MoCl2 as one of the most stable simple metallocenes. Unlike Cp2TiCl2, the Cp rings in the 
Mo derivative are less prone to hydrolysis. Furthermore, extensive spectroscopic studies, mainly by 1H 
and 31P NMR, were carried out in solution to assess the binding mode of molybdocene dichloride with 
DNA.96, 98-100 In more recent work, Harding and co-workers investigated cellular uptake and intra-
cellular localization of several bent metallocenes dihalides by X-ray fluorescence.101, 102 Only low levels 
of Ti and V were detected inside cells, and only Mo seemed to accumulate in significant amounts in the 
cellular nuclei (Figure 6). All together, these findings agree well with the notion that all metallocenes 
have a different biological profile.  
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Figure 5. Intracellular distribution of Mo (from Cp2MoCl2), Ti (from Cp2TiCl2) and K as shown by 
X-ray fluorescence microscopy. 
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Organometallic Ruthenium half-sandwich complexes. The idea of using ruthenium-containing 
organometallics as anticancer agents was first developed by Tochter et al.103 before being intensively 
investigated in the Sadler and Dyson research groups. It was initially anticipated that the binding of all 
ruthenium compounds to DNA was the main reason for their anticancer effect, similarly to the platinum 
derivatives, i.e - the coordination of the metal centre to DNA causes structural modifications, which 
would ultimately lead to the induction of apoptosis. Indeed, the ability of ruthenium complexes to bind 
to DNA or model compounds has been amply demonstrated,104-114 although it was found that the actual 
DNA binding of certain ruthenium compounds was weaker or/and different to the one observed for 
platinum derivatives.106, 115, 116 But, recent studies for a series of ruthenium anticancer compounds 
revealed that DNA is not always the primary target and that these species were actually binding more 
strongly to proteins than to DNA.117-119 These findings clearly indicated the occurrence of significantly 
different modes of action, depending on the type of ruthenium complexes. However, the exact 
mechanism by which these metallodrugs exert their effects has not (yet) been fully understood. 
Nonetheless, in this section, we will highlight recent developments on the elucidation of the mechanism 
of action of anticancer ruthenium half-sandwich organometallic compounds as well as the exact role of 
the metal centre. A non-exhaustive catalogue of ruthenium organometallic antitumor agents can be 
found in recent reviews or book chapters.5, 120-123 We will use structure comparisons to explicit the 
mechanism differences / analogies of these compounds. 
At a first glance, the structural similarity of the half-sandwich “piano-stool” type organometallics 
presented in Figure 7 might suggest an analoguous mechanism of cytotoxic action. However, to the best 
of our current knowledge, they appear to be much different.  
Ru
NH
NH
Cl
R
Ru
P
Cl
Cl
R
N
N
N
RAPTA Derivatives
R'
R'
RuII arene  ethylenediamine derivatives
+
 
18 
Figure 7. (6-arene) Ruthenium anticancer complexes. 
 
Salder et al. established that the mechanism of action of their compounds [(6-arene)Ru(en)(Cl)]+ (en 
= ethylenediamine) (Figure 7, left) has a lot of analogies to that of cisplatin. It first involves hydrolysis 
of the Ru-Cl bond of the prodrug to generate an active [(6-arene)Ru(en)(H2O)]2+ species. Detailed 
kinetic studies showed that the Ru-Cl bond hydrolysis can be strongly influenced by the nature of the 
co-ligands as well as the nature of the metal ion (see also the section on organometallic Os half-
sandwich compounds below).121, 122 Importantly, this step is suppressed in the blood due to the high 
chloride concentrations enabling [(6-arene)Ru(en)(Cl)]+ to cross the cell and nuclear membranes. Once 
inside the cell, the hydrolysis of the chloro anion takes place due to the much lower chloride 
concentration (ca. 25 times lower). It is then assumed that the aqua complex [(6-arene)Ru(en)(H2O)]2+ 
binds to nuclear DNA with a high affinity for the N7 position of guanine bases a shown by NMR and X-
ray crystallographic studies and transcription mapping experiments.111-113 It must be pointed out that the 
analogy in the mode of action between [(6-arene)Ru(en)(Cl)]+ and cisplatin stops at this point. Indeed, 
the Ru arene compounds can only form monofunctional adducts compared to cisplatin which is known 
to form bifunctional adducts and DNA cross-links. Importantly also, [(6-arene)Ru(en)(Cl)]+ derivatives 
were found to be active against cisplatin-resistant cell lines indicating that the detoxification mechanism 
is different to the one of cisplatin.124 However, in silico calculations undertaken by Deubel et al. to 
compare the difference in selectivity of cisplatin to organometallic ruthenium complexes towards 
biological targets show that organometallic ruthenium anticancer complexes are more similar to 
cisplatin than to inorganic Ru(II) complexes.125  
Ru-RAPTA derivatives were originally designed for improved aqueous solubility (pta = 1,3,4-triaza-
7-phosphatricyclo-[3.3.1.1]decane, Figure 7). As for Ru(II) arene ethylenediamine compounds, RAPTA 
derivatives126  containing two chloride ligands were also found to be susceptible to hydrolysis and it was 
first anticipated that DNA was a primary target.127 Dyson et al. recently prepared RAPTA carboxylato 
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derivatives (oxalo-RAPTA-C and carbo-RAPTA-C, Figure 8).128  This work was evidently inspired by 
the structures of carboplatin and oxaliplatin. In analogy to the Pt compounds, it was assumed that the 
carboxylato ligands would hydrolyze slower and in a more controllable way than the chloride ligands in 
the original RAPTA-C compound. These RAPTA derivatives had an in vitro activity similar to RAPTA-
C. All evidence taken together, RAPTA compounds seem to operate by a different mode of action 
compared to cisplatin, Ru(II) arene ethylenediamine compounds and to most of the known anticancer 
compounds in general. In vitro cytotoxicity studies showed that these compounds were much less 
cytotoxic than cisplatin. Indeed, many of the RAPTA compounds could not even be classified as 
cytotoxic and were also non-toxic to healthy cells. The extend of this non-toxicity was proven in an in 
vivo study when healthy mice were treated at quite high doses with RAPTA compounds without 
triggering toxic side effects.129 But, the most striking result observed was that both RAPTA-C and 
RAPTA-T inhibited lung metastasis in CBA mice bearing the MCa mammary carcinoma (the number 
and weight of the metastases were reduced), while having only mild effects on the primary tumor.2 The 
only other drug candidate displaying this outstanding behavior is imidazolium trans-
[tetrachloro(dimethylsulfoxide)(1H-imidazole)ruthenate(III) (NAMI-A).2, 118 This discovery is of high 
practical interest as the removal of the primary tumor by surgery is frequently an efficient procedure 
while the treatment options for metastases are quite limited.2  
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Figure 8. RAPTA derivatives. 
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Nonetheless, these very exciting findings engendered naturally a new and obvious question: If DNA is 
not the target for these RAPTA derivatives, then which is it? The final answer has not yet been given 
but, at this stage of the research, enzyme binding is the most probable explanation. It was shown by 
mass spectroscopy that RAPTA compounds form adducts with proteins130 and that the reactivity of 
RAPTA-C and cisplatin in the presence of proteins was much different.131 To get more insight, Messori 
et al. studied the inhibition activity of a series of RAPTA compounds to two proteins, i.e. cathepsin B 
(cat B) and thioredoxin reductase (TrxR), which are possible targets for anticancer metallodrugs.132 
They found that all tested Ru compounds were inhibitors of cat B while none of them, with the 
exception of RAPTA-C, was inhibiting TrxR. Computer docking experiments validated this finding. 
Assuming that one of the two chloride ligands of the RAPTA derivatives was first replaced by a water 
molecule, it was then found that the Ru(II) centre coordinates to the active site cysteine residue. 
Furthermore, other atoms of RAPTA (chloride, nitrogen of pta, etc…) bind other amino acids of cat B, 
thereby stabilizing the metallodrug-enzyme complex.132 Interestingly, a good agreement was observed 
between the inhibiting potency of the RAPTA derivatives and the calculated stability of the 
corresponding cat B/RAPTA adducts.132 
Other proteins have been proposed as the target for Ru organometallics. P-glycoprotein (Pgp) is a 
plasma membrane protein which is responsible for drug efflux from cells and which is involved in 
multi-drug resistance (MDR).120 Inhibitors of Pgp, namely phenoxazine and anthracene derivatives, 
were synthetically modified and coordinated to Ru organometallics.133 The aim was to obtain a 
synergistic effect by combining the selectivity of ruthenium complexes towards cancer cells and the 
ability of the phenoxazine and anthracene derivatives for Pgp inhibition. These newly formed 
complexes were found to be, in general, more cytotoxic and inhibited in a lesser extend the Pgp protein 
than the original Pgp inhibitor derivatives used as ligands. Interestingly, for one of these ruthenium 
derivatives (13, Figure 9), it was shown that the ruthenium coordination to the Pgp inhibitor derivative 
induced an even stronger protein inhibition. Furthermore, due to the presence of the fluorescent 
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anthracene group, it was observed that 13 was accumulating in cell nuclei suggesting a DNA synthesis 
inhibition as the mechanism of cytotoxic action. Nonetheless, due to the strong increase in cytotoxicity 
upon ruthenium coordination, Dyson et al. believe that their organometallic not only inhibits but also 
induces cell death via a second mechanism, implying a bifunctionality of their compound.133  
In a similar line of thought, namely a dual cytotoxic mode of action, ethacrynic acid (EA) was 
coupled to two RAPTA derivatives (15 and 16, Figure 9)134 as well as to other Ru-arene 
organometallics.135  EA is an effective glutathione transferase (GST) inhibitor, which has been 
investigated as a potential anticancer drug. EA is known to bind competitively to the hydrophobic 
cosubstrate (H-site) of GST while the RAPTA compounds are recognized to react with soft nucleophilic 
centers such as thiol groups (see above).134 15 and 16 compounds were therefore thought to be able to 
bind not only to the enzyme at the H-site but also to interact with the reactive cysteine residues of GST 
P1-1 (this GST protein possesses two solvent-accessible cysteine residues that affect catalytic activity 
when modified). As assumed, these two new compounds were found to bind the catalytic H-site, in a 
similar fashion to EA. Furthermore, the inhibition constants Ki of the complexes on GST P1-1 were 
three or four times lower than EA. The authors therefore concluded that the ruthenium centers were also 
involved in the inhibition of GST P1-1. Interestingly, it was demonstrated by X-ray crystallography and 
by ESI-MS that 16 decomposed, over a period of time, into a ruthenium derivative and EA. It is 
anticipated that the cleavage occurred, by virtue of a possible allosteric effect or simply over time, when 
the EA moiety of 16 is bound to the H-site. Importantly, this (selective?) release of the ruthenium 
moiety should enhance the toxic effect of the compound on cancer cells, which had already been 
sensitized by the EA moiety that inactivated GST.134 This feature could be used to specifically deliver a 
cytotoxic payload for targeted chemotherapy.134 
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Figure 9. Ru-arene enzyme inhibitors. 
 
Still in a metal-drug synergism context, the group of Sánchez-Delgado coupled different Ru-arene 
complexes to chloroquine (CQ), which is known to be an effective antimalarial compound as well as 
having anticancer properties (see metallocenes section above).136 Different to the ferroquine mentioned 
above,17, 137 in which the ferrocenyl moiety is non-toxic (or at least commonly assumed to be), these 
compounds are made of two toxic moieties. The compounds had a consistently higher potency against 
CQ-resistant parasites than that of the standard drug chloroquine diphosphate (CQDP). In addition, two 
of their compounds (17 and 18, Figure 10) inhibit the growth of two HCT-116 colon cancer cell lines 
with IC50 values between 20 and 35 M. They also observed that liposarcoma cell lines were especially 
sensitive to 17 with an IC50 value of 8 M. This is of clinical interest as this type of tumor does not 
respond to currently employed chemotherapies.136  
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Other proteins have been shown to be the target of cytotoxic ruthenium organometallics. For example, 
Sheldrick et al. have used an automated multidimensional protein identification technology (MudPIT), 
which combined biphasic liquid chromatography with electrospray ionization tandem mass 
spectrometry (MS/MS) to analyze tryptic peptides from Escherichia coli cells, which were first treated 
with [(6-p-cymene)RuCl2(DMSO)] (14, Figure 9).138 They showed that five proteins, namely the cold-
shock protein CspC, the three stress-response proteins ppiD, osmY and SucC as well as the DNA 
damage-inducible helicase dinG were the target of their Ru-arene compounds.138 Using electrophoretic 
mobility shift assays, Brabec, Sadler and co-workers also examined the binding properties of the 
mismatch repair (MMR) protein MutS in Escherichia coli with various DNA duplexes (homoduplexes 
or mismatched duplexes) containing a single centrally located adduct of Ru(II) arene compounds.139 
They showed that presence of the Ru(II) arene adducts decreased the affinity of MutS for ruthenated 
DNA duplexes, which either had a regular sequence or contained a mismatch, and, that intercalation of 
the arene contributed considerably to this inhibitory effect.139 
Interestingly, it was recently demonstrated that iodo-containing Ru(II) arene organometallic 
derivatives 19 and 20 (Figure 11) were highly cytotoxic to human ovarian A2780 and human lung A549 
cancer cells, although these complexes are remarkably inert towards ligand substitution – no hydrolysis 
was observed by NMR and ESI-MS.140 Fluorescence-trapping experiments in A549 cells suggested that 
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this potency arose from an increase in reactive oxygen species (ROS). Surprisingly, these Ru complexes 
act as catalyst for the oxidation of the tripeptide glutathione (GSH), which is a strong reducing agent 
present in millimolar concentrations in cells. Indeed, millimolar amounts of GSH were oxidized to 
glutathione disulfide in the presence of micromolar ruthenium concentrations! The same group showed 
that the anticancer complex [6-bip)Ru(en)Cl]+ 21 (bip=biphenyl) (Figure 11) readily reacts with GSH, 
at pH 7, in a typical cytoplasmic concentration of chloride and at Ru concentrations relevant to 
cytotoxicity, to give a thiolato complex [6-bip)Ru(en)(GS-S)] as the major product.113 Unexpectedly, 
this complex is very sensitive to air and is oxidized to the sulfenato complex [6-bip)Ru(en)(GS(O)-S)]. 
However, under physiologically relevant conditions, competitive reaction of complex 21 with GSH and 
guanosine 3’,5’-cyclic monophosphate (cGMP) gave rise to a cGMP ruthenium adduct, accounting for 
62% of total Ru, even in the presence of a 250-fold molar excess of GSH.113 This suggests that 
oxidation of coordinated glutathione in the thiolato complex to the sulfenate provides a facile route for 
displacement of S-bound glutathione by the guanine N7 atom, a route for RNA and DNA ruthenation 
even in the presence of a large excess of GSH.113 
 
 
Figure 11. Structures of catalytically active organometallic anticancer complexes. 
 
 It must be pointed out that Sadler et al. recently unambiguously identified di-ruthenium and tetra-
ruthenium clusters when complex 21 was reacted with GSH, using nanoscale liquid chromatography 
fourier transform ion cyclotron mass spectrometry combined with 18O-labeling.141 The same group also 
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recently observed the binding of Ru-arene compounds with human serum albumin by means of mass 
spectroscopy combined with trypsin digestion, specific side-chain modifications and computational 
modeling.142 Finally, a loss of cytotoxic activity of Ru-arene organometallics upon oxidation of their 
amine ligand such as o-phenylenediamine (o-pda) to the corresponding imine ligand o-
benzoquinonediimine (o-bqdi) (Figure 12) was observed.143 For example, the IC50 values against A2780 
ovarian cancer cells of 22 is of 11 M while compound 23 displays a value above 100 M. 
Interestingly, the o-bqdi complexes can be reduced by GSH but readily undergo reoxidation in air. 
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Figure 12. Ru-arene anticancer complexes with redox-active diamine  / diimmine ligands. 
 
Dyson et al. recently described the preparation of a series of RAPTA-type complexes with fluoro-
substituted 6-arene ligands.144 Electron-withdrawing fluoro- or CF3- units were added to the arene to 
modulate the pKa values of the complexes. The activity of these organometallics was found to be 
strongly influenced by the presence of the substituents. IC50 values of the fluoro compounds were in 
general much lower than those of the non-fluorinated analogues. 
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Organometallic Osmium half-sandwich complexes. Probably due to its reputation of being highly 
toxic (see OsO4)  and relatively inert towards substitution, osmium organometallics have been neglected 
as therapeutic agents in comparison to its lighter congener ruthenium.121, 145 Recently however, several 
research groups146-154 investigated the anticancer activity of osmium(II) arene half–sandwich complexes. 
Their results indicate that Os(II) organometallics might be promising candidates as antitumor drugs.  
 
The kinetic and thermodynamic properties found for the first Os complexes were unsatisfactory 
despite the fact that they were isostructural to the active Ru complexes.121 Concomitantly, the biological 
activity was low and the following SAR was established and then be used to improve their activity. The 
ligand exchange rate (chloride against water, see discussion above in the organometallic Ru half-
sandwich section) was notably too slow (40 to 100 times slower than the Ru analogues, depending on 
the pH value). The water bound to the osmium is indeed more acidic by 1-2 pKa units than when bound 
to analogous ruthenium complexes. In order to restore activity, a new series of Os complexes was 
prepared, in which the neutral N,N-chelate ethylenediamine was replaced by O,O and N,O anionic 
chelating ligands with a stronger trans effect. Following this thought, picolinate was identified as an 
ideal ligand candidate and the respective complexes [(6-arene)Os(pico)Cl] (22, Figure 13) had faster 
hydrolysis rates and potent anticancer activity comparable to carboplatin.148 Furthermore, their 
mechanism of action is thought to be similar to their Ru organometallics – nuclear DNA being the 
biological target as shown by studies demonstrating the binding of such complexes to DNA.150 
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 Figure 13. Os(II)-arene anticancer compounds. 
 
Arion, Keppler and co-workers investigated the binding of ruthenium and osmium to paullone 
derivatives, which are known to be potent inhibitors of cyclin-dependent kinases (CDKs) (23, Figure 
13).152 This “metalation” was thought to increase the solubility and bioavailability of the paullone 
ligands. They showed that complexes such as 23 had respectable antiproliferative activity in 
submicromolar to very low micromolar concentrations in three cell lines, with no significant differences 
between the Os and Ru complexes. No CDK inhibition was published so far on those compounds and 
their binding to 5’-GMP was found significantly different depending on the complexes. This indicates 
that they exert their anticancer activity either by binding to crucial proteins or by noncovalent DNA 
interactions.152 
 
Dyson et al. have also evaluated the activity of Os(II) and Rh(III) analogues of RAPTA-C (24, 25, 
Figure 13).153, 154 Depending on the cell lines, significantly different IC50 values were determined for 24, 
25 and RAPTA-C, with 25 being more cytotoxic than the two other compounds and 24 exhibiting 
essentially similar cytotoxicity as RAPTA-C.154 Furthermore, using a combined experimental and 
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theoretical approach, it was reported that the binding of RAPTA-C and 24 to a 14-mer oligonucleotide 
was nonspecific contrary to cisplatin, indicating a different mechanism of action and / or a different 
biological target.153 
Telomerase is a ribonucleoprotein with DNA polymerase activity that maintains the length of 
telomeric DNA by adding hexameric units to the 3’ single strand terminus. It is therefore a crucial 
enzyme for cancer progression. Rosenberg, Osella and co-workers investigated telomerase inhibition by 
a series of water-soluble cyclometallated benzoheterocycle triosmium clusters (26-29, Figure 14).155 
Their motivation was that quinoline derivatives had shown interesting biological properties, especially 
in inhibiting enzymes.156 Among all compounds, only the negatively charged clusters (by virtue of the 
sulfonated phosphines) exhibited good activity as telomerase inhibitors when tested on semi-purified 
enzymes in a cell-free assay. However, they were ineffective in vitro on Taq, a different DNA-
polymerase. Furthermore, none of the osmium clusters decreased the telomerase activity in the MCF-7 
breast cancer cell line, as observed by the Telomeric Repeat Amplification Protocol (TRAP assay). This 
may well be due to the low aptitude of these organometallics to cross the cell membrane. However, all 
compounds were acutely cytotoxic, probably due to their accumulation on cell membranes, as shown for 
compound 27a by inductively coupled plasma mass spectrometry (ICP-MS). It was hypothesized that 
27a interfered with the normal trafficking and functions of the membrane. Gobetto, Rosenberg and co-
workers also investigated the interaction of other positively and negatively charged triosmium carbonyl 
clusters with albumin, using the transverse and longitudinal relaxation times of the hydride resonances 
as 1H NMR probes of binding to the protein.157 Evidence of binding was observed for both the 
positively and negatively charged clusters. However, they exhibit distinctly different rotational 
correlation times.157 It was anticipated that the negatively charged clusters bind more tightly than their 
positive analogues as albumin is rich in positively charged amino acids.157 The same researchers also 
established guanines as the binding sites of another positively charged water-soluble benzoheterocycle 
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triosmium cluster to single- and double-stranded DNA by using a range of different biochemical 
methods.158 
 
 
Figure 14. Triosmium clusters as potential inhibitors of telomerase enzyme. Ligand sites on Os 
denoted by (–) indicate CO ligands. 
 
It is worth mentioning that Os3(CO)9 type cluster and dicobalt carbonyl fragments were also reacted 
with derivatives of tamoxifen, a widely used drug in the treatment of hormone-dependent breast 
cancer.159 The organometallic moiety was found to increase the lipophilicity and reduced affinity, via 
steric hindrance, for the estrogen receptor, but no cytotoxicity studies were carried out on the 
compounds. 
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Organometallic Iridium and Rhodium half-sandwich complexes. In contrast to their Ru(II) 
congeners, the isoelectronic Rh(III) and Ir(III) half-sandwich compounds have attracted much less 
attention as potential anticancer agents.154, 160-162 But, interestingly, among the few examples reported in 
the literature, different biomolecules were reported as (potential) targets. Nevertheless, even though it 
was shown that these compounds were indeed targeting the desired biomolecules, their exact mode of 
cytotoxic action is still unknown. Hence, Sheldrick et al. showed that Ir(III) and Rh(III) complexes such 
as 30 (Figure 15) bind DNA through intercalation of their polypyridyl ligands160, 161 Polypyridyl-
containing half-sandwich complexes with Ru(II) and Rh(II) central atoms and pentamethyl-
cyclopentadienyl or hexamethyl-benzene ligands showed stable intercalative binding into DNA and 
exhibited excellent cytotoxic activities.114, 161 Cellular uptake studies by atomic absorption spectroscopy 
(AAS) revealed that the antiproliferative effects of the complexes were mainly correlated to the size of 
the polypyridyl ligands, thereby highlighting the special role of ligand lipophilicity on the bioactivity of 
this class of organometallic antitumor drug candidates. Whereas an interaction with the DNA might 
significantly contribute to the cytotoxic activity of the agents, the presence of additional cellular targets 
or alternative modes of action is very likely and is therefore the subject of ongoing research projects.  
 
Another example of anticancer Ir(III) compounds has been found, probably by serendipity. Indeed, in 
order to design new biological probes for Bovine Serum Albumin (BSA), Lo et al. prepared a series of 
luminescent Ir(III) complexes  (31, Figure 15) containing an indole derivative – indole is known to bind 
to BSA – which were found to be highly cytotoxic towards HeLa cells.162 It is also interesting to 
mention that other cationic Ir(III) complexes such as 31 have been recently reported for 
phosphorescence staining in the cytoplasm of living cells and were shown to be non-cytotoxic.163 
 
Interestingly, the hetero-bi-organometallic ferrocene-containing Rh(I) derivative 32 (Figure 15)  had a 
similar cytotoxicity in prostate cancer cell lines as cisplatin but a significantly different pathway for 
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activation of cell death.164 While cisplatin predominantly induces apoptosis, 32 induces late necrosis and 
abnormal nuclear morphology.164 This latter finding is of interest as apoptosis-resistant cells might be 
better killed with drugs inducing the necrotic pathway.164  Furthermore, the same complex 32 and other 
related Rh(I) and Ir(I) analogues (33 and 34, Figure 15) were also found cytotoxic towards Chinese 
Hamster Ovary (CHO) cells with the Rh(I) complexes having IC50 values close to cisplatin while the 
Ir(I) complex had a slightly higher IC50 value.165 These compounds were also tested for their capacity to 
sensitize hypoxic CHO cells against irradiation. Indeed, tumors are notoriously hypoxic and 
radioresistant. Both factors limit the success of radiotherapy. Modulation of the radiosensitivity by 
drugs such as cisplatin is in routine clinical application.165 Indeed, the Rh(I) complex 32 proved to be an 
excellent radiosensitizer with properties similar to cisplatin.165 
 
 
Figure 15. Examples of Rh(III), Ir(III), Rh(I) and Ir(I) cytotoxic organometallic compounds. 
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Rhenium Organometallics. Re organometallics are another very new class of promising 
antiproliferative compounds. Until recently, only very few examples of cytotoxic Re complexes were 
described in the literature.166-168 However, over the last years, several compounds with interesting 
cytotoxicity were reported and their possible mode of action was explored.169-174 A non-exhaustive list 
of toxic Re compounds is presented in Figure 16. It is still premature to draw any definite conclusions 
on the molecular basis for the activity of the Re organometallics presented in this Figure. However, a 
few targets are now envisaged. Hor and co-workers assumed that their complexes such as 38 and 39 
(Figure 16) were likely to bind to DNA bases or side-chains of amino acid residues in peptides and 
proteins after displacement of the labile ligands.166, 167 Other related Re compounds such as [Re2(-
OH)3(CO)6]-, [Re2(-OH)(-OPh)2(CO)6]-, [Re2(-OMe)2(-dppf)2(CO)6]- and [Re2(-OPh)2(-
dppf)2(CO)6]- (dppf = 1,1´-bis(diphenylphosphino)ferrocene) have been shown to interfere with nucleic 
acid metabolism at multiple enzyme sites in L1210 lymphoid leukaemia cells, causing DNA strand 
scission after 60 minutes incubation.168 Ma et al. observed by spectroscopic titrations and viscosity 
experiments that their complex 37 (Figure 16) had a modest DNA binding constant and that 37 was 
interacting with DNA via groove binding.169 Modeling studies suggested that the minor groove was the 
favored binding site.169 Lo et al. prepared and carefully characterized a series of luminescent Re 
complexes such as 35, 36 and 42, which were generally highly cytotoxic.172-174 However, the exact 
target or mechanism of actions of these compounds are at this stage of the research unknown. Recently, 
Doyle, Zubieta and co-workers prepared two new fluorescent Re-tricarbonyl bioconjugates, namely a 
folate (41)170 and a vitamin B12 (43)171 conjugate (Figure 15). 41 was screened against a doxorubicin- 
and cisplatin-resistant human ovarian cancer cell line (A2780/AD) which overexpresses the folate 
receptor (FR). As expected, 41 was internalized by a folate receptor-mediated endocytotic pathway in 
this cell line. In contrary, no internalization of 41 was observed with a FR-negative Chinese Hamster 
Ovary (CHO) cell line. 41 was more cytotoxic than cisplatin towards the FR-positive cell line. The 
toxicity of 41 was attributed to the intercalation between the Re complex and DNA. The structure of the 
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Re complex of 41 is consistent with the criteria for minor-groove binding to DNA with the quinoline 
rings preferring the A•T sites of the helix, and with the positive charge contributed by the metal ion.170 
Interestingly, no inhibition of topoisomerase I activity was observed with the Re complex of 41.170 
 
The fluorescent Re bioconjugate 43 (Figure 16) was prepared to target the cubilin receptor through the 
vitamin B12 uptake pathway.171 Vitamin B12 is an important requirement for rapidly growing cancer 
cells and is therefore an interesting carrier for drug delivery assuming that receptors involved in its 
uptake can be targeted. In vitro antiproliferative cell assays against cubilin-expressing placental 
choriocarcinoma BeWo and CHO cell lines were undertaken and 43 was found only moderately 
cytotoxic towards BeWo cells (IC50 = 376 M). The parent Re compound 40 was found 10 times more 
cytotoxic than 43 (Figure 16),171 probably because of a more rapid uptake of 43 to the intracellular pool 
due to passive diffusion. Aggregation of 43 in the cytosol and in the nucleus was observed. The 
positively charged rhenium chelate component is envisaged to interact with the negatively charged 
DNA backbone, thus playing a role in the observed cytotoxicity.171 
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Figure 16. Cytotoxic Re organometallics. 
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Ruthenium, Osmium, Iridium, and Platinum Organometallics as scaffolds for protein kinase 
inhibitors.[NOTE TO THE EDITOR. Please insert a footnote with the following text: “The three 
reviews cited in this section provide references to the early original papers of Meggers et al.”] 
With the exception of DNA-intercalating compounds, the metal centre very likely plays a direct role in 
the anticancer activity of most compounds discussed so far by either binding DNA and / or proteins. In 
contrast, Meggers et al. have used metal complexes as structurally inert scaffolds for enzyme 
inhibitors.175-177 Their starting idea was that the spatial organisation of the substituents around the metal 
centre of a metal complex is much more versatile and therefore increases substantially the opportunity 
to build complicated three-dimensional enzyme inhibitor structures. Importantly, the metal is not 
playing any direct role in the inhibition; it “only” allows the spatial organisation of the substituents 
around the metal centre. Their chosen targets were protein kinases which are known to regulate many 
aspects of cellular physiology and pathophysiology.178 The mutations and deregulation of protein 
kinases plays a causal role in many human diseases, making them an important therapeutic target.177 
Eight kinase inhibitors are already clinically approved while several more are in the pipeline. Numerous 
indolocarbazole alkaloid derivatives such as staurosporine were found to be potent protein kinases 
inhibitors by hydrogen binding the ATP binding site (Figure 17).176 However, a central drawback in the 
design of these kinase inhibitors is the fact that kinases form one of the largest families of enzymes with 
highly conserved ATP binding sites, thus rendering the design of selective inhibitors very 
challenging.177 To overcome this limitation, Meggers et al. synthesized a significant number of metal-
containing enzyme inhibitors, the majority of them being Ru(II) complexes and some Pt and Os 
derivatives (See Figure 18 for a few examples of Ru(II) complexes). They successfully designed 
nanomolar and even picomolar ATP-competitive ruthenium-based inhibitors. This concept has been 
confirmed by, so far, six different co-crystal structures of Ru complexes with protein kinases.179, 180 As 
expected, the metal ion played solely a structural role (Figure 19). However, the organic ligands can be 
optimized to occupy the available space in the active site, as well as providing additional hydrogen 
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bonding interactions, thus making the individual inhibitors highly specific. Moreover, physiological 
functions as a consequence of kinase inhibition were demonstrated within mammalian cells, Xenopus 
embryos and zebrafish embryos.  
 
 
Figure 17. Binding of ATP (left), staurosporine (middle) and ruthemium complexes (right) to the 
ATP-binding site of cyclin dependent kinase 2 (CDK2). The green area indicates a patch of high 
hydrophobicity. Adapted from references.176, 181  
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Figure 18. Examples of Ru(II) organometallics as kinase inhibitors with their IC50 values. IC50 values 
were measured at 100 M ATP if not indicated otherwise. 
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Figure 19. Schematic view of how the metal complex mimics the overall shape of staurosporine. 
Adapted from references.177, 182  
 
Ru complexes seem like ideal candidates for this purpose as they are chemically stable in air, water 
and in buffer containing millimolar concentrations of thiols, as well as being configurationally stable 
against ligand exchange or scrambling around the metal centre.177 Other advantages are the well 
established synthetic chemistry of Ru complexes, a moderate price of the starting material (RuCl3) and 
low toxicity of such compounds.177 Recently this concept of drug design was extended to inert 
iridium(III) species featuring a highly potent and selective inhibitor of the kinase Flt4, which also 
demonstrated strong anti-angiogenic effects in zebrafish embryos.183  
 
38 
 Metal NHC complexes. Transition metal carbene complexes are organometallic compounds 
featuring a divalent organic ligand, which is coordinated to the metal centre (see Figure 1). N-
heterocyclic carbenes (NHCs) are generally derived from the so-called persistent carbenes, which are 
stable compounds of divalent carbon. As they are strongly stabilized by -donating substituents, NHCs 
are good σ-donors but π-bonding with the metal is weak. Metal NHC complexes are well known for 
their catalytic properties. Additionally, their high stability and ease of derivatization makes them 
suitable candidates for drug development.184, 185  
First reports on the biological application of NHC complexes dealt with the discovery of new anti-
microbal compounds and have also stimulated the evaluation of these compounds as antiproliferative 
agents.186-188 For example, the cationic gold imidazolidine derivative 47 displayed excellent activity 
against the growth of several species including Pseudomonas aeruginosa and Staphylococcus aureus 
(Figure 20).187 Most efforts in the development of carbenes as antibiotics have been focusing on NHC 
silver complexes. Silver complexes have a long tradition as anti-infectives, however, their mode of 
action is not completely understood so far. Interactions with the bacterial cell walls and the related 
biochemistry seem to be of relevance.189 The pyridine-linked silver carbene complexes 48 and 49 
exhibited higher bacteriostatic effects than silver nitrate.188 Promising antibacterial activities were also 
obtained with complex 50, which showed substantially higher stability in aqueous media than 
structurally related silver NHC complexes without Cl-substituents.192 Interestingly, 50 and structurally 
related species were also active against the growth of certain cultured tumor cells and preliminary 
studies on 50 using an ovarian cancer xenograft model also indicated in vivo antitumor activity.193 
Indeed, as outlined in more detail below, metal NHC complexes are promising candidates for the 
development of bioorganometallic anticancer therapeutics. In most cases, structures described as 
antiproliferative are closely related to the above mentioned antibacterial agents, thereby highlighting the 
broad applicability of the class of transition metal species. 
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Figure 20. Metal NHC complexes.  
 
In 2004, Barnard et al. reported the induction of mitochondrial permeability transition in isolated rat 
liver mitochondria by dinuclear Au(I) carbene complexes.194 This result is of special interest as gold 
complexes have been discussed as agents with an antimitochondrial mode of action since early studies 
on Au(I) phosphine drugs. Moreover, evidence that the impairment of mitochondrial functions is a 
major route of gold metallodrug activity keeps steadily increasing.195, 196 This antimitochondrial mode of 
action of many gold species is commonly related to the inhibition of the mitochondrial form of 
thioredoxin reductase (TrxR), a protein closely related to glutathione reductase. This protein is involved 
in various physiological processes (including proliferation) and is overexpressed in several cancerous 
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tissues. The active site of mammalian TrxR contains a selenocysteine residue, which is considered to be 
the target of gold metallodrugs.196, 197 
Antimitochondrial effects (induction of Ca2+-sensitive mitochondrial swelling) were also noted for a 
series of mononuclear, linear cationic [Au(NHC)2]+ complexes.198 The onset of mitochondrial swelling 
was most rapidly induced by the complexes with the highest lipophilicity, which was in line with 
previous studies on gold(I) species demonstrating that the bioactivity can be influenced by fine-tuning 
of the lipophilicity. A complex (51) with intermediate lipophilicity was selected for further studies 
confirming the significant anti-mitochondrial properties. It was found that 51 induced apoptosis via 
caspase-9 and caspase-3 activation. Furthermore, 51 inhibited TrxR activity in MDA-MB-231 cells and 
accumulated in mitochondria.199, 200 Structurally related Au(I) NHC complexes containing one NHC 
ligand and one chloro ligand (see 52 in Figure 20 for a relevant example) exhibited potent inhibitory 
activities against protein tyrosine phosphatases, a family of enzymes involved in various physiological 
processes.201 In analogy to the interaction of various gold complexes with cysteine and selenocysteine 
residues of TrxR or glutathione reductase (GR),196, 197 a cysteine residue in the catalytic site of protein 
tyrosine phosphatases is most probably the main molecular target for this kind of NHC complexes. 
Recently, Lemke et al. reported a series of gold NHC complexes with promising antiproliferative 
poteny including Au(III) species as well as derivatives containing cysteine thiolate ligands.202 Both the 
Au(III) and cysteine-modified NHC derivatives showed similar biological activities compared to related 
Au(I) NHC complexes without cysteine-derived ligands. This therefore strongly suggests that the 
development of structurally diverse bioactive gold NHC species is possible and activity as well as 
pharmacokinetic properties can be optimized by appropriate choice of the oxidation state of the metal 
and more sophisticated ligands. In this context it should be noted that NHC complexes can be 
functionalized with peptide ligands, which opens the possibility to develop metal NHC derivatives for 
targeted drug delivery.203 
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Besides the mentioned gold and silver derivatives, NHC complexes with palladium204, nickel205, 
copper206 or platinum207 have also been recently reported to exhibit anti-proliferative properties. Thus, 
the copper NHC complex 53 was more cytotoxic than cisplatin. Complex 53 induced apoptosis and, 
unlike cisplatin, arrested the cell cycle progression in the G1 phase. Concerning a plausible mode of 
action for this compound, its nuclease-like activity and O2-activating properties, which led to DNA 
strand breaks, appear to be of high relevance.185, 206 Trans-configured square planar platinum(II) species 
(see 54 in Figure 20 for a relevant example) demonstrated promising activity also in a cisplatin-resistant 
cell line.207 
Overall, metal NHC complexes display promising pharmacological properties as novel antibacterial 
and antitumor drugs. Regarding their mode of action, the choice of the coordinated metal most probably 
determines the respective main biological target - e.g. thioredoxin reductase or other enzymes 
containing (seleno)cysteine residues in their active site for gold or DNA for copper NHC complexes. 
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Metal carbonyl complexes. Metal CO complexes (or metal carbonyls) are organometallic complexes 
containing one or more carbon monoxide ligands. So far, a broad variety of different species with 
promising antiproliferative properties have been reported including the above mentioned rhenium and 
osmium derivatives but also various cobalt,208 iron,40 chromium (half-sandwich),209, 210 ruthenium211 or 
manganese212, 213 bioorganometallic species. 
For example, an increasing number of reports deal with the biological properties of alkyne 
hexacarbonyldicobalt (Co2(CO)6) species208, a class of bioorganometallic complexes whose cytotoxic 
properties had been mentioned first in 1987214 and then studied in more detail again since 1997.215 
During subsequent structure activity studies, a complex containing an acetylsalicylic acid (aspirin) 
derived ligand emerged as a lead compound for this class of drugs (55 in Figure 21).216, 217 The 
importance of the aspirin partial structure for the biochemical properties of this compound is also 
reflected in its name Co-ASS, which includes the German abbreviation for aspirin, ASS. Clinical studies 
on aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) had indicated a correlation 
between the long-term intake of NSAIDs and positive effects for cancer patients (mainly concerning a 
substantial decrease of recidive risks), thereby making NSAIDs interesting candidates for 
chemoprevention and combination chemotherapy.218 Based on these observations, the NSAID-like 
character of Co-ASS and related complexes was studied in more detail and appeared to contribute 
significantly to the activity of this lead compound.217 Co-ASS strongly inhibits the NSAID main target 
enzymes COX-1 and COX-2217 and, based on its good stability,219 it could be concluded that the active 
species was indeed the intact organometallic complex. Recently, it was confirmed that Co-ASS 
exhibited several biochemical properties related to the reported antitumoral effects of NSAIDs including 
induction of apoptosis, inhibition of PGE2 formation and triggering of anti-angiogenic effects.220 
Interestingly, it could be shown that Co-ASS acetylated several lysine residues of its putative main 
target COX-2 in contrast to aspirin, which acetylates a serine residue in the active site of the enzyme.220 
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In this context, it should be noted that a COX-2 related mechanism, as present for Co-ASS, most 
probably does not exist for other hexacarbonyldicobalt species not containing NSAID derived ligands. 
A variety of hexacarbonyldicobalt species with interesting biological properties have been reported 
including nucleosides (e.g. 56),221 carbohydrates,222 peptide derivatives (e.g. 57)223 or complexes with 
hormonally active ligands (Figure 21).224-226 Based on the chemical structures of these compounds, it is 
very likely that different biological structures are targeted, and one might speculate that the Co2(CO)6 
moiety modifies the interaction with those biomolecules. Thus, for complexes with hormone derived 
ligands, it was demonstrated that the hormonal activity and the receptor binding was retained. For 
nucleoside ligand containing derivatives, preliminary studies indicated that the uptake of the compounds 
into the tumor cells might correlate with their cytotoxic activity. As a similar dependence was also 
observed for the uptake into the nuclei, it can be concluded that, for the nucleoside derivatives, a 
possible mode of action might involve an interaction with the DNA or the DNA related enzyme 
machinery.221  
Hormonal activity has also been described for metal CO complexes other than hexacarbonyldicobalt 
alkynes mainly by the group of Jaouen. 227, 228 Thus, several metal carbonyl derivatives of estradiol or 
hydroxytamoxifen exhibited good estradiol receptor binding affinity and for some derivatives also anti-
proliferative activity was observed. For example, hydroxytamoxifene derivatives containing a 
cyclopentadienyl metal tricarbonyl moiety (see 58) were well recognized by both ERα and ERß and 
triggered antiproliferative effects (see also metallocenes section above).227 
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Figure 21. Metal CO complexes. 
 
In the case of iron containing metal carbonyl complexes, especially nucleoside containing derivatives 
have been the subject of major attention. Thus, the iron CO complex N69 (59 in Figure 21) significantly 
induced apoptosis in tumor cells but did not trigger unspecific necrotic effects (see also compound 2 in 
Figure 3).40 These properties are highly relevant for further development of these compounds into 
suitable drug candidates. Additionally, further unspecific effects of the iron-diene unit could be ruled 
out as close analogues of the lead compound as well as the (non-iron containing) free ligand were not 
active.40 Interestingly, the apoptosis induction in melanoma cells by 59 was independent of caspase 
activation but could be related to ROS formation. It was suggested that the N69-mediated ROS 
production could be due to its capacity as an iron donor with the nucleoside ligand functioning as a 
carrier.229 
In the above mentioned examples, the structural influence of the CO ligands on the bioactivity and 
molecular receptor interaction is not clear so far but increasing evidence exists that the presence of these 
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ligands is crucial for the efficacy of the compounds. In this context, it is important to note that the 
position of a CO ligand in the active site of the target enzyme Pim-1 could be confirmed by X-ray 
crystallography for a staurosporine-derived ruthenium kinase inhibitor (see Figures 17 and 18 for more 
details on this class of complexes). From this crystal structure it is obvious that the CO ligand (together 
with a cyclopentadienyl ring) occupies a binding pocket in the active site of the enzyme, which is 
usually filled by the carbohydrate moiety of staurosporin.175 Based on these data, it can be speculated 
that similar biomolecular target interactions might be relevant also for other metal CO complexes. 
Besides their potential role in the molecular interaction with biological targets another relevant feature 
of CO complexes is their high lipophilicity, which led to increased cellular uptake levels in a number of 
studies.217, 221, 222 It can thus be additionally speculated that stable CO ligands trigger an enhanced 
bioactivity due to the fact that the cellular uptake of the (bioactive) ligand of the complex is increased.  
An other interesting concept for the biomedical use of metal carbonyl species is the fact that the CO 
ligands can be released under appropriate conditions enabling the released carbon monoxide to trigger 
pharmacological effects.230 Thus, CO releasing properties have recently also been reported for 
hexacarbonyldicobalt complexes231 and for manganese carbonyl derivatives photoinduced cytotoxic 
effects were observed (see 60).212 These properties are elegantly used in a broader context by the design 
of carbon monoxide releasing molecules (CORMs), which might find future application in medicine due 
to their powerful vasodilatory, anti-inflammatory and anti-apoptotic properties. For a more detailed 
description of the group of CORMs the reader is referred to recent reviews on this topic.232, 233  
Metal carbonyl species have also shown potential for application as diagnostics. While this topic is 
also beyond the scope of this perspective the concept shall here be mentioned briefly: The fact that the 
intensive IR vibrations of the CO ligands are suitable for detection purposes found use in the so-called 
carbonyl metallo immuno assay (CMIA). 234 For example, using this method it was possible to develop 
assays for the sensitive detection of hormones or antiepileptics and to obtain metal-carbonyl-dendrimer-
antibody bioconjugates with a broad range of applications.235  
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Miscellaneous. Other strategies and ideas for the treatment of cancer involving the use of 
organometallics were recently employed by Therrien et al. They investigated the possibility to combine 
the chemotherapeutic activity of organometallics with photosensitizing agents for photodynamic therapy 
(PDT). With this in mind, they prepared a series of Ru(II) (61), Os(II) (62), Rh(III) (63) and Ir(III) (64) 
complexes containing porphyrin derivatives, which are known to be efficient photosensitizing agents 
(Figure 22).236 The photoactivation produces singlet oxygen and radical species which results in tumor 
cell death. All complexes had similar moderate cytotoxicity towards cancer cells with the exception of 
the Rh complex which was found to be non-toxic. Importantly, the Ru(II) complexes exhibit excellent 
phototoxicity towards melanoma cells when exposed to laser light at 652 nm.236 The exact mechanism 
of action of these Ru complexes is not yet determined but it has been shown by fluorescence 
microscopy that they were not accumulating in the nucleus suggesting a non-DNA mode of action. In a 
similar perspective, very recently, the same group described the use of sawhorse-type diruthenium 
tetracarbonyl complexes containing porphyrin-derived ligands as highly selective photosensitizers for 
female reproductive cancer cells.237  
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It was also shown by the same group that the bridging of two Ru organometallics through a ferrocene 
moiety (65, Figure 23) increased considerably the cytotoxicity of the compounds compared to the 
monoruthenium analogue.238 A difference in redox-potential of the ferrocene units has been proposed as 
a possible cause of the increased cytotoxicity. Remarkably, these compounds were equally potent 
against cisplatin-resistant and non-resistant cell lines, which is indicative of a different mode of action 
from that of cisplatin.238 The concept of multinuclearity for the improvement of anticancer activity has 
also been demonstrated by Hartinger et al.239-241 
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Figure 23. A di-arene ruthenium compound bridged by a ferrocene.238 
 
Another original example of the use of organometallics for cancer therapy was to employ an 
“organometallic cage” to transport metal complexes, namely [Pd(acac)2] and [Pt(acac)2] (acac = 
acetylacetonato) into cancer cells “by encapsulation”. The trigonal-prismatic “cage” molecule consists 
of six half-sandwich (6-arene)Ru (66, Figure 24) or (5-pentamethylcyclopentadienyl)Rh units held 
together by two trigonally substituted triazine and additional chloro or oxaloto bridges. Interestingly, 
once inside the cells, [Pd(acac)2] or [Pt(acac)2] are released and exert a cytotoxic effect.242 It was shown 
that these cages were extremely stable, even at high temperatures. It was further demonstrated that the 
empty cage and the Pd and Pt complexes by themselves were less toxic than their “complex-in-a-
complex”.242 The exact mechanism of action for these compounds is still unknown but it is postulated 
that the organometallic cage facilitates the cellular uptake. The use of such metalla-boxes is currently 
being investigated in this group.243 
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Figure 24. Structure of the Complex-in-a-Complex  cations [(acac)2M Ru6(p-
iPrC6H4Me)6(tpt)2(dhbq)3]6+ (66). Reproduced, by permission from the publisher, with modification 
from ref.242  
 
Sadler, Brabec et al. also investigated the photoactivation of dinuclear ruthenium(II) arene complexes 
to trigger DNA binding and fluorescence.244 They showed that upon irradiation with UV-A light, some 
of their complexes underwent arene loss. Interestingly, the fluorescence of the unbound arene is roughly 
40 times greater than when it is complexed to the Ru centre, therefore enabling to visualize the intra-
cellular localization of the arene moiety. Furthermore, irradiation also had a significant effect on DNA 
binding in that the formed ruthenium adducts are strongly blocking RNA polymerase. These complexes 
therefore have the potential to combine both photoinduced cell death and fluorescence imaging of the 
location and efficiency of the photoactivation process. 
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Conclusion and Perspective. 
In this perspective article, we summarized recent developments towards the use of organometallic 
compounds as anticancer drug candidates. The general notion that organometallic compounds would be 
sensitive to air and water and therefore unstable under physiological conditions and unsuitable for 
medicinal purposes has been disproved. Rather, our above analysis demonstrates a broad range of 
classes of compounds that are stable and well characterized for biological applications. Organometallic 
compounds are frequently kinetically inert and amendable to (multiple) derivatization reactions. They 
are thus suitable for conventional structure-based drug design, including computer docking experiments 
similar to the more traditional organic drug candidates. The successful development of ruthenium kinase 
inhibitors by Meggers and co-workers impressively demonstrates this capacity. A recent multi-step 
synthesis of chromium-based antibiotics modeled after the natural lead structure platensimycin further 
demonstrates that even complicated lead structures can be realized with organometallics cores.210 
Overcoming the long neglectance of these so-called bioorganometallics by both industrial and academic 
drug research, an increasing number of emerging drug classes impressively demonstrates that the field 
offers a broad variety of unexplored options for synthetic medicinal chemistry. 
By combining modern organometallic synthesis with state-of-the-art biochemical studies, the field has 
advanced markedly from the rather crude “synthesis-and-cytotoxicity-screening” approach that was 
common just a few years ago. Organometallic chemists frequently collaborate with medicinal chemists, 
biochemists and molecular or cell biologists. Thereby arriving at the forefront of medicinal chemistry 
research, they employ the whole tool-box of modern medicinal chemistry research, including structural 
biology, computer-aided design, and biochemical and cell-based assays to gain a deep insight into 
possible cellular targets and the molecular details of target interactions. For a number of compounds, 
even in vivo testing is ongoing. We have pointed to prior and published in vivo work in the relevant 
sections, and more work is currently under way but not publicly available yet. However, we would 
certainly expect that this is the next frontier for medicinal organometallic chemistry, on the way to bring 
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at least some of the most promising organometallic drug candidates described herein as drugs to the 
market.  
In this perspective, we have tried to emphasize such biochemical studies (where available) to 
elucidate molecular targets and modes of action. While it is clear that for many organometallic 
complexes interesting bioactivities were observed, the molecular modes of target interaction or the 
targets themselves are not perfectly clear for each class of compounds at this stage. It is clear, however, 
that DNA is not the target for most bioorganometallics and protein inhibition (e.g. cyclooxygenases or 
thioredoxin reductase) or other mechanisms (e.g. hormone receptor interaction) are major modes of 
action. Moreover, some metal complexes may even exhibit completely novel, metal-specific modes of 
action, such as the ferrocifen derivatives in which the metallocene acts as a redox antenna for intra-
molecular redox activtion. Clearly, exploitation of the distinct properties of metal complexes for 
biologically active compounds deserves more attention. It is hoped that the advent of organometallic 
complexes in clinical trials will improve acceptance of such compounds in the pharmaceutical industry 
and support further research into the fascinating field of organometallic drugs and their biological 
targets.  
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